Sep 02, 2020 8:30am EDT Algernon Announces Enrollment of 50th Patient in Multinational 2b/3 Human Study of Ifenprodil for Treatment of COVID-19
Aug 25, 2020 8:00am EDT Algernon to Provide Update on its Ifenprodil IPF and Chronic Cough Phase 2 Human Study Featured on BioPub Webcast Hosted by Dr. KSS MD PhD
Aug 24, 2020 7:00am EDT Algernon Announces Research Analyst Coverage by Mackie Research with an $0.80/share Target Price
Aug 17, 2020 8:00am EDT Algernon CEO Presents Corporate Update Featured on BioPub Webcast Hosted by Dr. KSS MD PhD
Aug 13, 2020 8:15am EDT Algernon Announces Enrollment of First U.S. Patient in Multinational Phase 2b/3 Human Study of Ifenprodil for Treatment of COVID-19
Aug 05, 2020 1:57pm EDT Algernon Announces Enrollment of First Patient in 2b/3 Human Study of Ifenprodil for Treatment of COVID-19
Aug 05, 2020 8:37am EDT Algernon Announces First Patient Dosed in Phase 2 IPF and Chronic Cough Human Trial of Ifenprodil
Jul 21, 2020 8:00am EDT Algernon Highlights UT Dallas Research Study Identifying Ifenprodil as a Possible COVID-19 Treatment
Jul 16, 2020 8:00am EDT Algernon Announces First U.S. Clinical Trial Site in Florida for Phase 2b/3 Human Study of Ifenprodil for COVID-19
